An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS)

Trial Profile

An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Triheptanoin (Primary)
  • Indications De Vivo disease
  • Focus Therapeutic Use
  • Acronyms GLUT1DS
  • Most Recent Events

    • 25 Jan 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2023.
    • 25 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2022.
    • 23 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top